News & Events

Corporate Presentation
News Releases
NEW YORK , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced the appointment of Robert M. Francomano as Chief Commercial Officer.

Additional Formats

NEW YORK , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, highlighted three upcoming ELZONRIS (tagraxofusp), presentations, including an oral

Additional Formats

NEW YORK , Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Stemline management will present at Piper Jaffray’s 31 st

Additional Formats

Net revenue for ELZONRIS ® was $13.3 million for the third quarter New patient starts estimated to have increased greater than 20% from last quarter Conference call and live webcast scheduled for tomorrow, Friday November 8 th , at 8:00 AM ET NEW YORK , Nov.

Additional Formats

NEW YORK , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp; SL-401), a novel targeted therapeutic

Additional Formats

Upcoming Events
More events are coming soon.